Unpublished data may explain Lemtrada's efficacy...

A board to discuss the soon-to-be released drug Campath as a treatment for Multiple Sclerosis

Unpublished data may explain Lemtrada's efficacy...

Postby MSUK » Thu Jun 15, 2017 3:42 am

Previously unpublished data may explain Lemtrada's efficacy and side effects

Analysis of previously unpublished data from the pivotal phase III trials in the regulatory submissions of alemtuzumab, otherwise known as Lemtrada, indicated that efficiency was associated with long-term depletion of memory T- and B-cells. Whereas rapid hyper-repopulation of immature B-cells in the relative absence of regulatory CD4 and CD8 T-cells create the environment for the generation of secondary B-cell autoimmunity, including anti-drug antibodies...Read more - http://www.ms-uk.org/previously-unpublished-data-may-explain-lemtradas-efficacy-and-side-effects-150617
MS-UK - http://www.ms-uk.org/
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 3:00 pm


Return to Campath (Lemtrada, Alemtuzumab)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service